Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a systemic disease that is “metastatic” from diagnosis; therefore, the problems typically associated with local and regional control, i.e., those associated with surgery and radiation therapy, do not play a role. Since virtually all patients who die as a result of a malignant disease die of systemic (metastatic) cancer, AML has served as a prototype illness for the development of systemic therapies, and advances in the control of this disease have been rapidly applied to the control of the more common metastatic cancers in man.
KeywordsLeukemia Corticosteroid Methotrexate Cyclophosphamide Prednisone
- 1.Freireich EJ, Frei III E. Recent advances in acute leukemia. In: Moore CV, Brown EB, editors. Progress in hematology. New York: Grune and Stratton; 1964. p. 189–202.Google Scholar
- 2.Freireich EJ, Bodey GP, Hart JS, Rodriguez V, Whitecar JP, Frei III E. Remission induction in adults with acute myelogenous leukemia. In: Mathe G, editor. Recent results in cancer research, vol. 30. Berlin: Springer; 1970. p. 85–91.Google Scholar
- 4.McCredie KB, Bodey GP, Freireich EJ, Gutterman JU, Hester JP, Drewinko B. Adult leukemia. In: Clark RL, Howe CD, editors. Cancer patient care at M.D. Anderson Cancer Center. Chicago: Year Book Medical Publishers; 1976. p. 165–97.Google Scholar